Islets of Hope
|Volume 1, Issue 11: November 2005|
Product Watch: Animas gives away iPod nanos.
Editorial: AFT seeks to stop all non-medical personnel from providing diabetes care in school.
Clinical Trial Update: Arkansas
Trouble with Novolog? Is your pharmacist mixing up Mix 70/30 and Rapid?
DANA Diabecare Warned by FDA: Failure to Report Insulin Pump Problems
Inhaled Insulin May Only Be A Breath Away From FDA Approval
Buyer Beware Counterfiet Lipitor
Halloween Candy Scare?
Flu Season Brings New Cautions for Anti-Nausea Drug in Pediatric Use
JDRF Walk for A Cure Hgh- lights From Ontario, CA (09/10/05)
Phenergan can cause death in children under age 2.
Islets of News Editorial Feature
The Great Label Debate: Are you a diabetic? Or do you just have diabetes?
Important Medical Disclaimer
This book combines a compre- hensive medical approach toward intensive diabetes management and pump therapy with a patient-centered appreciation of the real-life challenges and frustrations.
Frio USA Insulin Cool Pouch Products Leave Customers Out in the Cold
Lilly Cautions that Cymbalta may increase risk for liver damage: October 18, 2005. ST. LOUIS (MD Consult) - "On October 17, 2005, Eli Lilly and the US Food and Drug Administration (FDA) notified health care professionals of a revision to the Precautions/Hepatotoxicity section of the prescribing information for Cymbalta (duloxetine hydrochloride), indicated for treatment of major depressive disorder and diabetic peripheral neuropathic pain..."
Diabetes Drugs Approved in 2005
Increlex (mecasermin), a drug from Tercicia was approved fby the FDA in August 2005 for the treatment of growth failure in pediatric patients. Increlex contains recombinant-DNA- engineered human insulin-like growth factor-1 (rhIGF-1). It is designed to replace natural IGF-1 in pediatric patients who are deficient, promoting normal statural growth.
ActoPlus Met - "Takeda Pharm- aceutical Co. has obtained U.S. FDA Administration approval for a new combination of insulin sensitizing drugs, Actoplus Met is a combination of Actos and Metformin." Associated Press, August 30, 2005.
Byettaa (exenatide) - Derived from a compound found in the saliva of the Gila monster, a large lizard native to the southwestern US, mimicks the function of GLP-1, the drug helps more strongly activate this pathway to improve glycemic control and is indicated for type 2 treatment.
Symlin (pramlintide) - A synthetic form of the hormone amylin normally produced by the beta cells along with insulin. Amylin, insulin, and a third hormone called glucagon all work together to maintain normal glucose levels. Studies show a modest improvement in A1C levels for individuals adding pramlintide to their diabetes care routine.
Two New Possibilities In Stem Cell Research
New stem cell techniques avoid ethical concerns: By Clive Cookson, Science Editor, Monday, October 17, 2005. “Science EditorUS scientists have developed two new ways of generating embryonic stem cells, designed to avoid some of the ethical objections to current methods that involve destroying "potential human life". ... The more positive technique comes from Advanced Cell Technology (ACT), a Massachusetts biotechnology company, …. The ACT group is the first to publish the successful derivation of stem cells from a mammalian embryo without killing it. The mouse embryos developed normally after stem cells were derived from them..."
Inhaled Insulin Approval Delayed by FDA
FDA Delays Approval of Inhaled Insulin:
Clinical Trial Update
The AbATE Clinical Trial
California - San Francisco
Warning Issues About Abbott Glucose Meters
Stem Cell Institute Opens In Mission Bay, CA
Stem cell research in California has a home in San Francisco overlooking the Bay and ballpark. The San Francisco Examiner, November 1, 2005, Marisa Lagos. ..."Mayor Gavin Newsom, institute officials and civic leaders were on hand to open the building for business Tuesday. Staff from the California Institute for Regenerative Medicine, or CIRM, which state voters created last year through a ballot proposition, will officially move into the office on Nov. 14....
“We are here today to celebrate that California, because of the default of Washington, D.C., has become the headquarters of stem cell research worldwide and San Francisco has become the capital for stem cell research,” CIRM board Chairman Bob Klein said. “There is no time to lose....”
Page Updated 12/09/2005